PSMA-targeted therapy for non-prostate cancers
Radioligand therapy (RLT) agents are demonstrating a crucial role in the clinical approach to aggressive malignancies such as metastatic castrate-resistant prostate cancer (m-CRPC). With the recent FDA approval of prostate-specific membrane antigen (PSMA)-targeted RLT for m-CRPC, the field has broad...
| Huvudupphovsmän: | , |
|---|---|
| Materialtyp: | Artikel |
| Språk: | English |
| Publicerad: |
Frontiers Media S.A.
2023-08-01
|
| Serie: | Frontiers in Oncology |
| Ämnen: | |
| Länkar: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1220586/full |